Alkermes · conference-presentation
Alkermes | Investor Day Presentation Deck | 144 slides
132 pages · 3 arc beats · 2 loops
Alkermes | Investor Day Presentation Deck | 144 slides
Alkermes · 2021-03 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
1102030405060708090100110120130132
Deck intelligence map
3 coverage by narrative range · generated from this deck JSON
Narrative range 20 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Situation & Context 4 slides 100% 4/4 slides 100% 4/4 slides · 18 hits — 0/4 slides
25% 1/4 slides — 0/4 slides
100% 4/4 slides — 0/4 slides
Problem & Complication 5 slides 100% 5/5 slides 100% 5/5 slides · 20 hits — 0/5 slides
40% 2/5 slides · 3 hits 20% 1/5 slides 100% 5/5 slides — 0/5 slides
Solution & Approach 11 slides 100% 11/11 slides 100% 11/11 slides · 49 hits — 0/11 slides
63.6% 7/11 slides · 8 hits 9.1% 1/11 slides 100% 11/11 slides 54.5% 6/11 slides Slide inventory
132 every slide · same image gating as the playbook
04
The slide uses a 2x2-style grid layout to contrast commercial products with development pipeline candidates.summarize
Open slide detailBeat · Situation & Context
08
The diagram uses a nested square structure to represent the synthesis of two core pillars.establish_context
Open slide detailBeat · Problem & Complication
12
Includes a mix of stacked bar charts, process lists, and donut charts for board metrics.summarize
Open slide detailBeat · Solution & Approach
14
The slide uses donut charts to illustrate revenue mix changes over time.summarize
Open slide detailBeat · Solution & Approach
15
The slide categorizes products into current commercial, pipeline, and licensed products.analyze_data
16
The slide uses a combination of a bar chart for financial performance and a line chart for demand growth, with annotations highlighting growth rates and the COVanalyze_data
17
The chart uses a dual-line comparison to show the impact of the pandemic on product demand.analyze_data
18
The slide uses a combination of a bar chart for annual revenue and a line chart for monthly prescription volume to demonstrate product performance.analyze_data
19
The slide uses a combination of a summary table and a grouped bar chart to demonstrate competitive outperformance.analyze_data
20
Includes clinical efficacy/safety data and commercial value proposition.quantify_opportunity
21
Includes detailed footnotes regarding data sources and limitations.size_opportunity
Open slide detailLoop · Cost Of Inaction
23
The slide categorizes revenue sources into three segments: Current Proprietary Commercial Products, Under FDA Review, and Royalty Stream.analyze_data
Open slide detailLoop · Cost Of Inaction
26
Uses a process-like visual flow to connect strategic priorities to business outcomes.present_framework
28
The slide uses a two-column list structure to categorize launch activities.plan_implementation
31
The bridge chart illustrates the path from 7% to ~25% margin using three levers: commercial operating leverage, R&D prioritization, and G&A/manufacturing efficishow_valuation_bridge
34
The slide highlights board independence, diversity, and tenure metrics alongside governance updates.summarize
35
The slide uses symbols (star and circle) to denote new directors and retiring directors, explained in the top right legend.introduce_nominees
36
The slide uses a 2x2-style grid layout to contrast commercial products with development pipeline candidates.establish_context
40
The diagram uses a central hexagon surrounded by six peripheral hexagons, representing a multi-factor evaluation framework.present_framework
42
The table serves as evidence of the 'quicker kills' strategy mentioned in the bullet points.prioritize
44
The slide uses a hub-and-spoke style diagram to connect strategic inputs to a central outcome.present_solution
46
The diagram uses a hexagonal cluster to represent the central 'High-Value Development Candidate' surrounded by key strategic inputs.present_framework
47
The slide uses a side-by-side comparison structure to highlight technical capabilities.present_solution
48
The slide highlights a tech stack including KNIME, Docker, AWS, and RDKit integrated into a proprietary platform.present_solution
51
The slide uses a structured table to categorize drug development candidates by their biological mechanism.present_solution
52
The slide uses molecular modeling imagery to illustrate different engineering approaches (Mutation, Fusion, ScFv Bispecific, Fusionbody, IgG Bispecific).establish_context
53
The slide uses a combination of biological diagrams and a structured comparison matrix to explain the therapeutic rationale for each cytokine.present_solution
54
The chart uses horizontal bars to represent the progress of different R&D programs across clinical phases.plan_implementation
57
The diagram illustrates a transition from legacy treatments to engineered specificity.present_solution
Open slide detailLoop · Quick Win Big Bet
58
The slide uses a visual metaphor of steric occlusion to explain the mechanism of action.present_solution
Open slide detailLoop · Quick Win Big Bet
59
Uses a causal chain/additive framework to build the argument.present_solution
Open slide detailLoop · Quick Win Big Bet
60
Uses a Venn-like diagram to contrast existing therapy strategies with new development strategies.present_solution
Open slide detailLoop · Quick Win Big Bet
62
Data cutoff March 1, 2021. PR=partial response, RP2D=Recommended Phase 2 Dose.analyze_data
Open slide detailLoop · Quick Win Big Bet
65
The slide uses a two-column layout to contrast general melanoma burden with the specific, more severe challenges of mucosal melanoma.diagnose_problem
Open slide detailLoop · Quick Win Big Bet
66
The slide outlines the patient population (refractory to prior therapies) and the statistical design (Simon Two-Stage) used to determine cohort expansion.present_framework
Open slide detailLoop · Quick Win Big Bet
67
The chart is a swimmer plot (a type of timeline/bar chart used in oncology clinical trials).analyze_data
Open slide detailLoop · Quick Win Big Bet
68
The slide uses a structured clinical case format to demonstrate drug efficacy.illustrate_case
Open slide detailLoop · Quick Win Big Bet
71
The slide uses a two-column layout to contrast disease burden with treatment limitations, supported by extensive clinical citations.diagnose_problem
73
The table tracks individual patient outcomes (OC1-OC5) in a platinum-resistant ovarian cancer cohort.analyze_data
74
Patient profile and clinical efficacy data for a specific case study.illustrate_case
75
The slide highlights a specific focus on ARTISTRY-2 (subcutaneous) with an orange border.plan_implementation
79
The slide highlights the efficacy of the SC 3 mg q7d regimen in expanding effector cells compared to IV administration.analyze_data
80
The slide outlines the transition from dose escalation cohorts (q7d and q21d) to a specific Phase 2 expansion cohort at 3.0 mg q7d.plan_implementation
81
Patient profile includes diagnosis, prior treatment history, current study activity, and clinical outcomes.illustrate_case
84
The slide uses a comparison matrix to contrast three different therapeutic assets.present_solution
85
The slide uses a process flow diagram to explain the biological mechanism of action.present_framework
86
The slide uses a process flow diagram to explain the biological mechanism of action.present_solution
87
The slide uses a linear process flow to explain the biological mechanism of the drug.present_solution
88
The slide uses a process flow to show the mechanism of action for Nemvaleukin in the context of immuno-oncology.present_solution
89
The slide uses a chevron-based process flow to show the transition from preclinical to clinical research.present_framework
90
The diagram illustrates the biological process from tumor cell death to T-cell activation.present_solution
91
The slide uses a vertical process diagram to illustrate the mechanism of ICD.present_solution
92
The slide uses a biological process flow diagram to explain the therapeutic rationale.present_framework
93
The slide demonstrates synergistic effects of combination therapy on immune cell infiltration.analyze_data
95
The slide presents two key metrics: tumor volume over time and Kaplan-Meier survival curves.analyze_data
96
The slide uses a vertical process diagram to explain the biological mechanism of ICD.present_solution
97
The slide uses a 'problem-solution' structure, identifying the dual nature of chemo/radiation and proposing Nemvaleukin as a counter-measure.present_solution
99
The slide uses a process flow diagram to map research stages to clinical outcomes.plan_implementation
101
The slide uses a matrix-like structure to compare three distinct therapeutic approaches.present_solution
102
The slide uses a diagram to illustrate the biological pathway from IL-12 to immune cell activation and subsequent downstream effects.establish_context
105
The slide uses a four-step process flow to explain a drug delivery mechanism.present_solution
106
The slide shows two line charts comparing tumor and blood concentration over time for two different subunits.analyze_data
107
The slide shows significantly higher accumulation of targeted subunits compared to non-targeted IL-12 in murine CT-26 tumor models.analyze_data
108
Statistical significance markers (asterisks) indicate differences between treatment groups.analyze_data
114
The slide uses a categorization framework to group diseases by type.establish_context
115
The slide uses a biological mechanism diagram to explain the therapeutic rationale for HDAC inhibitors.present_framework
116
The slide uses a phylogenetic-style tree to categorize HDACs and a cluster diagram to show protein complex composition.present_framework
120
The slide uses a three-column layout with checkmarks to indicate goal achievement.summarize
129
The slide features the company logo and a scientific illustration of antibodies.front_matter